Tools / Trials and research S1PR1: Sphingosine 1-phosphate receptor 1 A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
G protein-coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins.
Drugs that act on it : 6 Approved : 4 In phases 1 to 3 : 2 Sponsors : 6 Type : Protein Who Is On It, and How Far Along Every drug ChEMBL records acting on S1PR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Ozanimod Ozanimod SponsorBristol-Myers Squibb ModalitySmall molecule ActionModulator Open trials17 Etrasimod Etrasimod SponsorPfizer ModalitySmall molecule ActionAgonist Open trials12 Siponimod Siponimod SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionAgonist Open trials6 Ponesimod Ponesimod SponsorVanda Pharmaceuticals ModalitySmall molecule ActionAgonist Open trials4 Phase 32 Cenerimod Cenerimod SponsorViatris ModalitySmall molecule ActionModulator Open trials5 Mocravimod Mocravimod SponsorPriothera SAS ModalitySmall molecule ActionAgonist Open trials1
Modalities Modalities Share Copy link Download image (PNG)Drugs on this target by ChEMBL molecule type.
Small molecule 6 100%Small molecule Count6 Share100%
The Landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Sphingosine 1-phosphate receptor Edg-1 agonist; the rest name their own mechanism.
Open Trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 30 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC Etrasimod Phase 4 Not yet recruiting Sir Run Run Shaw Hospital 2026-08-24 A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis Etrasimod Phase 1 Not yet recruiting Helixon Biotechnology (Suzhou) Co., Ltd 2026-08-17 Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia Ozanimod — Recruiting Bristol-Myers Squibb 2026-07-29 A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC Etrasimod — Not yet recruiting Tang-Du Hospital 2026-07-15 Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod Phase 3 Recruiting Vanda Pharmaceuticals 2026-07-07 Etrasimod as Prevention of Pouchitis Etrasimod Phase 2 Recruiting Maia Kayal 2026-03-23 A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis Etrasimod Phase 2 Recruiting Pfizer 2026-03-13 An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis Etrasimod — Active, not recruiting Pfizer 2026-03-10 Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Ponesimod Phase 3 Recruiting Vanda Pharmaceuticals 2026-01-23 Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis Ozanimod — Recruiting Bristol-Myers Squibb 2025-12-08 A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) Cenerimod Phase 2 Active, not recruiting Viatris Pharmaceuticals Co., Ltd. 2025-12-05 Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis Etrasimod Not applicable Recruiting Showa Inan General Hospital 2025-11-24 A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment Cenerimod Phase 3 Recruiting Viatris Innovation GmbH 2025-10-01 Ozanimod in Patients With Alzheimer's Disease Ozanimod Phase 2 Recruiting ChenXiaoChun 2025-03-07 Repurposing Siponimod for Alzheimer's Disease Siponimod Phase 2 Recruiting St. Joseph's Hospital and Medical Center, Phoenix 2024-10-15 Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod Ozanimod Phase 4 Recruiting University of Colorado, Denver 2024-07-31 Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus Cenerimod Phase 3 Enrolling by invitation Viatris Innovation GmbH 2024-06-26 Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis Ozanimod Phase 3 Recruiting Bristol-Myers Squibb 2024-05-10 An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis Etrasimod — Active, not recruiting Pfizer 2024-05-03 A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis Ozanimod Phase 4 Active, not recruiting Bristol-Myers Squibb 2024-05-02 A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants Ozanimod — Active, not recruiting Bristol-Myers Squibb 2023-11-15 A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants Ozanimod — Active, not recruiting Bristol-Myers Squibb 2023-11-13 A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Ponesimod, Siponimod — Active, not recruiting Biogen 2023-01-18 A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Cenerimod Phase 3 Active, not recruiting Viatris Innovation GmbH 2023-01-05 A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus Cenerimod Phase 3 Active, not recruiting Viatris Innovation GmbH 2022-12-13 Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Mocravimod Phase 3 Recruiting Priothera SAS 2022-06-23 Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent Siponimod — Recruiting Novartis Pharmaceuticals 2021-06-21 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Siponimod Phase 3 Active, not recruiting Novartis Pharmaceuticals 2021-06-15 Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Ponesimod, Siponimod Phase 4 Active, not recruiting The Cleveland Clinic 2018-05-24 Determinants of Warfarin Metabolism Siponimod Not applicable Recruiting Hadassah Medical Organization 2005-09-13
Show all 30Diseases Most Associated With It Open Targets association score, 0 to 1; all associations
Crohn disease 0.39
Kidney transplant 0.34
Breast benign neoplasm 0.30
Non-small cell lung carcinoma 0.29
Preeclampsia 0.29
Response to stimulus 0.25
Genes and Related Targets Complexes and families that share a gene with this target
Genes S1PR1 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4333 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt P21453 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets